Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002598
Abstract: Low-grade gliomas/glioneuronal tumors comprise one-third of all pediatric-type CNS tumors. These tumors are generally caused by activating mutations in the mitogen-activated protein kinase (MAPK) pathway. Targeted drugs, such as trametinib, have shown promise in other… read more here.
Keywords: progressive low; glioneuronal tumors; grade glioma; low grade ... See more keywords